We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
C.R. Bard (BCR) to Report Q4 Earnings: A Surprise in Store?
Read MoreHide Full Article
Murray Hill, NJ-based CR Bard Inc. is scheduled to report fourth-quarter 2016 earnings, after market close on Jan 26.
Last quarter, the company reported adjusted earnings of $2.64, exceeding the Zacks Consensus Estimate by 9 cents and also improving 15.8% from the year-ago quarter. Notably, adjusted earnings were better than management’s guided range.
Meanwhile, the company’s earnings topped the Zacks Consensus Estimate in all the last four quarters with an average beat of 4.07%. Delving deeper into the fundamentals of the stock, let’s see how things are shaping up prior to this quarter.
We believe that the growing adoption of the company’s flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst for Bard in this quarter as well. In this regard, Lutonix DCB is used to treat patients suffering from peripheral arterial disease (PAD). In fact, within the Endovascular business, peripheral PTA line sales are solely driven by accelerating demand for the Lutonix drug-coated balloon (DCB) in the U.S. We expect to see this product to significantly contribute to the company’s topline in the yet-to-be-reported quarter.
Furthermore, the company's investments in the emerging markets have strengthened its position internationally and are expected to deliver accretive returns in the quarter. We are also upbeat on the solid contribution from the company’s vascular product line. The urology and oncology segments are also likely to drive sales in the quarter.
On the flip side, a challenging Med-tech environment, especially in the hernia fixation and peripheral stent businesses raises concerns. The company continues to witness significant pricing pressure as well. Also, unfavorable foreign currency will continue to hurt top-and bottom-line growth.
Furthermore, uncertainties associated with the possibilities of a repeal of the Affordable Care Act under President Trump add to our concerns.
Estimate Revision Trend
While the company’s fundamentals remain more or less sound, the current quarter’s estimate revision trend points to a different story. Over the past one month, three estimates moved south with none moving in the opposite direction. As a result, the current quarter estimates decreased almost 0.34% to $2.73, over the last 30 days.
Earnings Whispers
Our quantitative model doesn’t point to an earnings beat either this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Bard is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $2.73. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Bard carries a Zacks Rank #3 which increases the predictive power of ESP. However, the company’s ESP of 0.00% makes surprise prediction difficult.
Meanwhile, we caution against stocks with a Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Molina Healthcare Inc. (MOH - Free Report) has an Earnings ESP of +5.33% and a Zacks Rank #2.
Universal Health Services, Inc. (UHS - Free Report) has an Earnings ESP of +4.97% and a Zacks Rank #2.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
C.R. Bard (BCR) to Report Q4 Earnings: A Surprise in Store?
Murray Hill, NJ-based CR Bard Inc. is scheduled to report fourth-quarter 2016 earnings, after market close on Jan 26.
Last quarter, the company reported adjusted earnings of $2.64, exceeding the Zacks Consensus Estimate by 9 cents and also improving 15.8% from the year-ago quarter. Notably, adjusted earnings were better than management’s guided range.
Meanwhile, the company’s earnings topped the Zacks Consensus Estimate in all the last four quarters with an average beat of 4.07%. Delving deeper into the fundamentals of the stock, let’s see how things are shaping up prior to this quarter.
C.R. Bard Inc. Price and EPS Surprise
C.R. Bard Inc. Price and EPS Surprise | C.R. Bard Inc. Quote
Factors at Play
We believe that the growing adoption of the company’s flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst for Bard in this quarter as well. In this regard, Lutonix DCB is used to treat patients suffering from peripheral arterial disease (PAD). In fact, within the Endovascular business, peripheral PTA line sales are solely driven by accelerating demand for the Lutonix drug-coated balloon (DCB) in the U.S. We expect to see this product to significantly contribute to the company’s topline in the yet-to-be-reported quarter.
Furthermore, the company's investments in the emerging markets have strengthened its position internationally and are expected to deliver accretive returns in the quarter. We are also upbeat on the solid contribution from the company’s vascular product line. The urology and oncology segments are also likely to drive sales in the quarter.
On the flip side, a challenging Med-tech environment, especially in the hernia fixation and peripheral stent businesses raises concerns. The company continues to witness significant pricing pressure as well. Also, unfavorable foreign currency will continue to hurt top-and bottom-line growth.
Furthermore, uncertainties associated with the possibilities of a repeal of the Affordable Care Act under President Trump add to our concerns.
Estimate Revision Trend
While the company’s fundamentals remain more or less sound, the current quarter’s estimate revision trend points to a different story. Over the past one month, three estimates moved south with none moving in the opposite direction. As a result, the current quarter estimates decreased almost 0.34% to $2.73, over the last 30 days.
Earnings Whispers
Our quantitative model doesn’t point to an earnings beat either this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Bard is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at $2.73. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Bard carries a Zacks Rank #3 which increases the predictive power of ESP. However, the company’s ESP of 0.00% makes surprise prediction difficult.
Meanwhile, we caution against stocks with a Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:
Cempra Inc. has an Earnings ESP of +15.79% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Molina Healthcare Inc. (MOH - Free Report) has an Earnings ESP of +5.33% and a Zacks Rank #2.
Universal Health Services, Inc. (UHS - Free Report) has an Earnings ESP of +4.97% and a Zacks Rank #2.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>